Depressive DisordersSubstance Use Disorders (SUD)

Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics

This review/opinion article (2023) suggests that the reversal of and resilience against learned helplessness could be a key therapeutic mechanism of classic psychedelics in treating mood and substance use disorders. The authors argue for the utility of the learned helplessness model in psychedelic research due to its robustness across species, well-described neurobiology, and substantial overlap with neural circuits involved in psychedelic actions.

Authors

  • Frederick Barrett
  • David Yaden
  • Alaina Doss

Published

Psychedelic Medicine
meta Study

Abstract

Background: Emerging literature suggests that classic psychedelics may have efficacy in treating mood and substance use disorders in humans. This has raised questions regarding the primary therapeutic mechanism of these compounds. Here, we hypothesize that the reversal of and resilience against learned helplessness may be an important driver of the therapeutic mechanisms of classic psychedelics. Furthermore, we argue that the learned helplessness paradigm can provide a robust model to investigate the behavioral and mechanistic effects of classic psychedelics in both clinical and preclinical experiments.Opinion: We highlight the learned helplessness model and its potential utility in the psychedelic sphere for several reasons. First, learned helplessness is a robust phenomenon observed across multiple mammalian species including humans, and has been well described in terms of its neurobiology, behavioral effects, and clinical implications; current efforts in psychedelic research and theories of psychedelic mechanisms have yet to achieve this level of integration. Interestingly, there is substantial overlap in the neural circuits governing resilience against learned helplessness and psychedelic actions-such as those involving the dorsal raphe nucleus. Furthermore, our hypothesis that classic psychedelics can reverse helplessness behavior fits with much of the current preclinical data, which has shown that psychedelics improve performance in behavioral despair tasks in rodents. Here we make the case for bringing attention to these congruencies in an effort to advance toward mechanistic, behavioral, and transdiagnostic insights into the therapeutic effects of classic psychedelics, with the potential for learned helplessness to help explain some positive effects across levels of analysis.

Available with Blossom Pro

Research Summary of 'Learned Helplessness As a Potential Transdiagnostic Therapeutic Mechanism of Classic Psychedelics'

Introduction

Classic serotonergic psychedelics (5-HT2A receptor-mediated compounds such as psilocybin and LSD) have shown promising effects in mood and substance use disorders, but their primary therapeutic mechanisms remain unclear. Prior theoretical accounts have emphasised either neurobiological processes (for example, enhanced plasticity or reopening of critical-period-like windows) or psychological/subjective mechanisms (for example, mystical-type experiences, insight, psychological flexibility, and emotional breakthrough). Few frameworks have successfully integrated these levels of analysis, and existing neurobiological proposals lack specificity about which brain circuits and behaviours they target and how such changes map onto durable clinical benefit. This paper proposes that reversal of, and resilience against, learned helplessness could be a core transdiagnostic mechanism through which classic psychedelics exert therapeutic effects. The authors argue that the learned helplessness paradigm is well suited to bridge preclinical and clinical levels of analysis because it is robust across mammalian species, has well-described neural circuitry, and captures behavioural features that overlap with depressive and stress-related disorders. They set out to synthesise evidence from animal models, neurophysiology, imaging, and limited behavioural pharmacology to show congruence between the neural substrates of learned helplessness and the known effects of classic psychedelics, and to make the case for using learned helplessness as a productive model in future psychedelic research.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Study Details

References (34)

Papers cited by this study that are also in Blossom

Trial of Psilocybin versus Escitalopram for Depression

Carhart-Harris, R. L., Giribaldi, B., Watts, R. et al. · New England Journal of Medicine (2021)

927 cited
Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer

Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)

Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression a SPECT study

Sanches, R. F., Osório, F. L., Dos Santos, R. G. et al. · Journal of Clinical Psychopharmacology (2016)

380 cited
Psychedelics promote structural and functional neural plasticity

Ly, C., Greb, A. C., Cameron, L. P. et al. · Cell Reports (2018)

A non-hallucinogenic psychedelic analogue with therapeutic potential

Cameron, L. P., Tombari, R. J., Lu, J. et al. · Nature (2020)

70 cited
Towards an understanding of psychedelic-induced neuroplasticity

Calder, A. E., Hasler, G. · Neuropsychopharmacology (2022)

Show all 34 references
Oxytocin-dependent reopening of a social reward learning critical period with MDMA

Nardou, R., Lewis, E. M., Rothhaas, R. et al. · Nature (2019)

Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety

Davis, A. K., Barrett, F. S., Griffiths, R. R. · Journal of Contextual Behavioral Science (2020)

Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction

Garcia-Romeu, A., Griffiths, R. R., Johnson, M. W. · Current Drug Abuse Reviews (2015)

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects

Griffiths, R. R., Johnson, M. W., Richards, W. A. et al. · Psychopharmacology (2011)

The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects

Yaden, D. B., Griffiths, R. R. · ACS Pharmacology and Translational Science (2020)

Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin

Barrett, F. S., Johnson, M. W., Griffiths, R. R. · Journal of Psychopharmacology (2015)

Emotional breakthrough and psychedelics: validation of the emotional breakthrough inventory

Roseman, L., Haijen, E. C. H. M., Idialu-Ikato, K. et al. · Journal of Psychopharmacology (2019)

Pharmacological, Neural, and Psychological Mechanisms underlying Psychedelics: A Critical Review

van Elk, M., Yaden, D. B. · Neuroscience and Biobehavioral Reviews (2022)

Serotonin research: contributions to understanding psychoses

Geyer, M. A., Vollenweider, F. X. · Trends in Pharmacological Sciences (2008)

Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders

Vollenweider, F. X., Preller, K. H. · Nature Reviews Neuroscience (2020)

Models of psychedelic drug action: modulation of cortical-subcortical circuits

Doss, M. K., Madden, M. B., Gaddis, A. et al. · Brain (2021)

Emotions and brain function are altered up to one month after a single high dose of psilocybin

Barrett, F. S., Doss, M. K., Sepeda, N. D. et al. · Scientific Reports (2020)

Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder

Doss, M. K., Považan, M., Rosenberg, M. D. et al. · Translational Psychiatry (2021)

249 cited
Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow

Lewis, C. R., Preller, K. H., Kraehenmann, R. et al. · NeuroImage (2017)

74 cited
Psilocybin-induced decrease in amygdala reactivity correlates with enhanced positive mood in healthy volunteers

Kraehenmann, R., Preller, K. H., Scheidegger, M. et al. · Biological Psychiatry (2015)

Acute effects of LSD on amygdala activity during processing of fearful stimuli in healthy subjects

Mueller, F., Lenz, C., Dolder, P. C. et al. · Translational Psychiatry (2017)

Bespoke library docking for 5-HT2A receptor agonists with antidepressant activity

Kaplan, A. L., Confair, D. N., Kim, K. et al. · Nature (2022)

Cited By (1)

Papers in Blossom that reference this study

Clinically relevant acute subjective effects of psychedelics beyond mystical experience

Yaden, D. B., Goldy, S. P., Weiss, B. et al. · Nature Reviews Psychology (2024)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.